Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ: REGN · Real-Time Price · USD
789.45
+14.84 (1.92%)
At close: Sep 17, 2026, 4:00 PM EDT
786.80
-2.65 (-0.34%)
After-hours: Sep 17, 2026, 4:53 PM EDT
Regeneron Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 28 analysts polled by S&P Global, Regeneron Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $849.32. The average 1-year stock price forecast is 7.58% higher than the current stock price, while the lowest is $730 (-7.53%) and the highest is $1,030 (+30.47%).
Price Target: $849.32 (+7.58%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Regeneron Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 18 | 16 | 16 | 14 | 14 | 14 |
| Buy | 4 | 5 | 5 | 4 | 4 | 4 |
| Hold | 7 | 8 | 8 | 10 | 9 | 9 |
| Sell | 0 | 0 | 0 | 0 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 29 | 29 | 29 | 28 | 28 | 28 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Hold Maintains $737 | Hold | Maintains | $737 | -6.64% | Sep 10, 2026 |
| HSBC | HSBC | Buy Maintains $800 → $920 | Buy | Maintains | $800 → $920 | +16.54% | Sep 10, 2026 |
| Scotiabank | Scotiabank | Hold Maintains $770 | Hold | Maintains | $770 | -2.46% | Aug 20, 2026 |
| BMO Capital | BMO Capital | Buy Maintains $800 | Buy | Maintains | $800 | +1.34% | Aug 18, 2026 |
| Leerink Partners | Leerink Partners | Hold Maintains $641 → $824 | Hold | Maintains | $641 → $824 | +4.38% | Aug 17, 2026 |
Financial Forecast
Revenue This Year
16.93B
from 14.34B
Increased by 18.01%
Revenue Next Year
18.48B
from 16.93B
Increased by 9.20%
EPS This Year
53.80
from 44.31
Increased by 21.42%
EPS Next Year
60.62
from 53.80
Increased by 12.68%
EPS and Forward PE are based on non-GAAP adjusted numbers.